Patent ID: 9289388
Filing Date: 2016-03-22
CPC Classification: A61K,A61P

Claim Text:
1. A method of treating a human suffering from or at risk of a lung disease, the method comprising: providing a conjugate comprising a pulmonary active drug for lung treatment selected from the group consisting of an antihistamines; a P2X agonist; a P2Y agonist; a matrix metalloproteinase inhibitors; a kinase inhibitor; an endothelin receptor antagonist; a prostacyclin analogue selected from the group consisting of beraprost, epoprostenol, iloprost, and treprostinil; and a phosphodiesterase type 5 inhibitor; wherein said pulmonary active drug is covalently bonded to a surface active agent characterized by an affinity for the human alveolar/gas interface and comprising at least a portion of a mammalian lung surfactant polypeptide substantially non-immunogenic to humans, wherein the pulmonary active drug binds to an extracellular or cell surface-bound target accessible to the human alveolar/gas interface when the conjugate is present at the interface; and administering the conjugate to the human by inhalation in an amount effective to induce a drug effect in the lungs, wherein said administration increases residence time of the pulmonary active drug in the lung relative to inhalation administration of unconjugated pulmonary active drug.